Value of Heart Rate Lowering Therapy in Acute Myocarditis

Assiut University

Status: Enrolling

Conditions: Myocarditis

Treatments: Drug: Ivabradine

Study type: Observational

Funder types: Other

Identifiers

NCT06312891

VOHRLTIAM

Details and patient eligibility

About

To study the value of heart rate lowering therapy "pharmacological rest" on the short term in cases of myocarditis without LV dysfunction.

Enrollment: 150 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults: ≥18 years of age.

• Presentation: at least one of the following:

  • Myopericarditis/ACS-like
  • MINOCA
  • Arrhythmias: brady or tachyarrhythmias.
  • Unexplained compensated acute cardiomyopathy (excluded ischemic, valvular, hypertensive, metabolic, and toxic causes of cardiomyopathy as indicated clinically).

• TTE: LVEF>40%

• CMR-confirmed myo(peri)carditis (Lake Louise criteria)

Exclusion criteria

• • Rheumatic carditis.

  • Connective tissue diseases (-ve ANA).
  • Cancer chemotherapy.
  • Toxicity from immunotherapy.
  • Vaccine-related myocarditis.
  • Presence of coronary artery disease.
  • Peripartum (occurring during the last month of pregnancy or within 5 months after delivery)
  • ECG: atrial fibrillation/flutter.
  • Resuscitated sudden death.
  • Early/initial phase of decompensated heart failure.
  • Tamponade complicating pericarditis unless successfully managed.

Trial design

150 participants in 3 patient groups

Conventional anti-inflammatory treatment (control group).

Conventional ttt PLUS Carvedilol.

Conventional ttt PLUS Ivabradine.

Treatment:

Drug: Ivabradine